Pembrolizumab/Chemo, Followed by Olaparib Maintenance, Boosts PFS in Advanced Ovarian Cancer
Pembrolizumab plus chemotherapy, followed by olaparib with or without bevacizumab, improved PFS in advanced ovarian cancer.
Related Articles
NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET
NFKB1 rs230511 reduces inflammation and amplifies responses to ropeginterferon alfa-2b in polycythemia vera and essential thrombocythemia.
Phase II trial of durvalumab + lenalidomide vs single-agent durvalumab in refractory/advanced CTCL
Christiane Querfeld, MD, PhD, City of Hope, Duarte, CA, presents the results of a randomized Phase II trial (NCT03011814) investigating the safety and efficacy of…
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Lancet Breast Cancer Commission Report Addresses Challenges to Reduce Disease Burden
Reshma Jagsi, MD, DPhil, highlights key takeaways from the Lancet Breast Cancer Commission Report and the necessary steps forward emphasized in the report.
Certain Breast Cancer Subtypes May Derive a Greater Benefit With Ribociclib Combo vs Chemo
Patients with luminal B and HER2E breast cancer subtypes may have a greater PFS benefit with ribociclib plus endocrine therapy vs combination chemotherapy.
FDA Grants Fast Track Designation to IMM-1-104 in NRAS+ Advanced Melanoma
The FDA has granted fast track designation to IMM-1-104 for the treatment of advanced melanoma.
The Ongoing Debate: Progression-Free vs Overall Survival as the Primary Study Outcome in Therapeutic Cancer Trials
Is it time to end the rhetoric that denies the benefit of antineoplastic pharmaceutical agents due to the absence of an OS improvement in a…
New ADCs Join NCCN Guidelines for Gynecologic Cancers Representing Step Forward
Stephanie Gaillard, MD, PhD, details cervical and ovarian cancer NCCN guideline updates, as well as unmet needs associated with molecular markers.
Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma
Isatuximab plus initial VRd and Rd maintenance demonstrated deep responses and MRD negativity in transplant-ineligible newly diagnosed multiple myeloma.
Belantamab Mafodotin Combo Could Be New SOC for Relapsed/Refractory Multiple Myeloma
Belantamab mafodotin plus bortezomib/dexamethasone improved OS over daratumumab plus bortezomib/dexamethasone in relapsed/refractory multiple myeloma.